

Jeanne Tie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2033169/publications.pdf>

Version: 2024-02-01

115
papers

10,932
citations

159585

30
h-index

36028

97
g-index

116
all docs

116
docs citations

116
times ranked

15201
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	12.4	3,665
2	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	12.6	1,872
3	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	12.4	1,036
4	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. <i>Cancer</i> , 2011, 117, 4623-4632.	4.1	624
5	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	7.1	438
6	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710.	7.1	383
7	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2261-2272.	27.0	337
8	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	12.1	234
9	Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF ^{V600E} mutation. <i>International Journal of Cancer</i> , 2011, 128, 2075-2084.	5.1	200
10	<i>KRAS</i> Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1122-1130.	7.0	193
11	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118.	7.1	152
12	Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 3662-3670.	7.0	107
13	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	8.4	88
14	Effect of Aspirin on Cancer Incidence and Mortality in Older Adults. <i>Journal of the National Cancer Institute</i> , 2021, 113, 258-265.	6.3	80
15	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. <i>Acta Oncologica</i> , 2018, 57, 1438-1444.	1.8	78
16	Prognostic significance of postsurgery circulating tumor <i>DNA</i> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	5.1	77
17	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 463-474.	3.6	64
18	Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. , 2020, 8, e001006.		62

#	ARTICLE	IF	CITATIONS
19	Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer. PLoS ONE, 2015, 10, e0120425.	2.5	59
20	Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. International Journal of Cancer, 2016, 138, 671-678.	5.1	56
21	Assessing aneuploidy with repetitive element sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4858-4863.	7.1	50
22	Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Metaanalysis of Oncological and Operative Outcomes. Annals of Surgical Oncology, 2021, 28, 7476-7486.	1.5	49
23	Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncologica, 2015, 54, 487-492.	1.8	46
24	ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm. Cancers, 2021, 13, 346.	3.7	46
25	Antiangiogenic Therapies Targeting the Vascular Endothelia Growth Factor Signaling System. Critical Reviews in Oncogenesis, 2012, 17, 51-67.	0.4	46
26	A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Targeted Oncology, 2015, 10, 99-109.	3.6	45
27	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, e9-e15.	2.3	45
28	Differentiation of tumor recurrence from radiation necrosis in high-grade gliomas using 201Tl-SPECT. Journal of Clinical Neuroscience, 2008, 15, 1327-1334.	1.5	42
29	Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. Clinical Colorectal Cancer, 2015, 14, 185-191.	2.3	42
30	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nature Biotechnology, 2021, 39, 1220-1227.	17.5	40
31	Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Targeted Oncology, 2015, 10, 179-188.	3.6	35
32	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. Diagnostics, 2021, 11, 103.	2.6	33
33	Landscape of KRAS ^{G12C} , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO Precision Oncology, 2022, 6, e2100245.	3.0	31
34	RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 95-103.	2.3	30
35	Reinventing the randomized controlled trial in medical oncology: The registry-based trial. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 365-373.	1.1	30
36	Impact of diabetes on clinicopathologic and genetic features of colorectal cancer formation.. Journal of Clinical Oncology, 2013, 31, 426-426.	1.6	28

#	ARTICLE	IF	CITATIONS
37	Clinical guidance for radioiodine refractory differentiated thyroid cancer. <i>Clinical Endocrinology</i> , 2018, 88, 529-537.	2.4	27
38	Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 899-906.	1.7	27
39	Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3488-3498.	7.0	26
40	Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, e569-e577.	2.3	23
41	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3516-3516.	1.6	19
42	Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1195-1203.	1.3	18
43	Examining the impact of regular aspirin use and <i>PIK3CA</i> mutations on survival in stage 2 colon cancer. <i>Internal Medicine Journal</i> , 2017, 47, 88-98.	0.8	16
44	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. <i>International Journal of Cancer</i> , 2019, 145, 540-547.	5.1	15
45	Liquid biopsies for residual disease and recurrence. <i>Med</i> , 2021, 2, 1292-1313.	4.4	15
46	Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond. <i>Future Oncology</i> , 2018, 14, 2725-2739.	2.4	14
47	Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. <i>ANZ Journal of Surgery</i> , 2019, 89, 1035-1040.	0.7	14
48	Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 953-964.	3.3	14
49	Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. <i>Journal of Cancer Epidemiology</i> , 2015, 2015, 1-8.	1.1	13
50	Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1-3.	3.1	13
51	Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine. <i>Clinical Chemistry</i> , 2016, 62, 796-798.	3.2	12
52	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. <i>Seminars in Cancer Biology</i> , 2018, 52, 241-252.	9.6	12
53	Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 527-539.	1.9	12
54	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019, 49, 446-454.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100637.	2.0	11
56	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3521-3521.	1.6	11
57	Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 279-298.	3.8	11
58	Redefining Colorectal Cancer by Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 147-159.	3.8	9
59	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4101-4101.	1.6	9
60	A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. <i>British Journal of Cancer</i> , 2022, 127, 126-136.	6.4	9
61	Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. <i>Clinical Colorectal Cancer</i> , 2016, 15, e125-e132.	2.3	8
62	CD8 ⁺ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survival. <i>Clinical and Translational Immunology</i> , 2020, 9, e1155.	3.8	8
63	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 314-321.	1.1	7
64	Tailoring immunotherapy with liquid biopsy. <i>Nature Cancer</i> , 2020, 1, 857-859.	13.2	7
65	Second primary colorectal cancer in the era of prevalent screening and imaging. <i>ANZ Journal of Surgery</i> , 2013, 83, 963-967.	0.7	6
66	Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 361-367.	1.1	6
67	Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in <i>Australia</i> . <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 262-271.	1.1	6
68	Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. <i>Journal of Personalized Medicine</i> , 2019, 9, 37.	2.5	6
69	Emerging strategies in the initial management of locally advanced rectal cancer. <i>Future Oncology</i> , 2019, 15, 2955-2965.	2.4	6
70	Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer. <i>Growth Factors</i> , 2019, 37, 209-225.	1.7	6
71	The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 6619-6631.	1.5	5
72	Registry-based randomized clinical trials as a method to improve cancer care in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 188-189.	1.1	4

#	ARTICLE	IF	CITATIONS
73	Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. <i>Visceral Medicine</i> , 2020, 36, 388-396.	1.3	4
74	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2021, 20, e21-e34.	2.3	4
75	Biomarkers in Locally Advanced Rectal Cancer: A Review. <i>Clinical Colorectal Cancer</i> , 2022, 21, 36-44.	2.3	4
76	The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2022, , .	1.0	4
77	Microsatellite Instability Status Is Critical to Analysis of Survival in Stage II Colon Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 675-676.	1.6	3
78	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020, 38, 1263-1275.	3.3	3
79	Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?. <i>Current Oncology Reports</i> , 2021, 23, 140.	4.0	3
80	A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. <i>BMC Cancer</i> , 2022, 22, 222.	2.6	3
81	Precision oncology using a clinician-directed, tailored approach to molecular profiling. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 84-90.	1.1	2
82	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. <i>Targeted Oncology</i> , 2021, 16, 227-236.	3.6	2
83	Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour.. <i>Journal of Clinical Oncology</i> , 2016, 34, 650-650.	1.6	2
84	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centre. <i>ANZ Journal of Surgery</i> , 2022, , .	0.7	2
85	Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. <i>Internal Medicine Journal</i> , 2020, 50, 165-172.	0.8	1
86	Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 932.	7.1	1
87	Impact of adjuvant chemotherapy and patient age on patterns of metastatic recurrence in stage III colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 122-122.	1.6	1
88	Clinical relevance of circulating tumour DNA in colorectal cancer. <i>ANZ Journal of Surgery</i> , 2021, 91, 774-775.	0.7	1
89	Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.3	1
90	Prescribing patterns for bevacizumab in first-line metastatic colorectal cancer: Exploring the introduction of a new drug into routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2012, 30, 665-665.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A two-year review of routine practice.. Journal of Clinical Oncology, 2012, 30, 682-682.	1.6	1
92	Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?. Journal of Clinical Oncology, 2013, 31, 410-410.	1.6	1
93	Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, e14558-e14558.	1.6	1
94	Treatment sequencing and outcomes in synchronous metastatic rectal cancer.. Journal of Clinical Oncology, 2017, 35, 750-750.	1.6	1
95	Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 386-386.	1.6	1
96	Delivery and effectiveness of adjuvant therapy for stage III colon cancer in routine clinical practice.. Journal of Clinical Oncology, 2014, 32, e14540-e14540.	1.6	1
97	Immune profile and survival outcomes in stage 2 colon cancer.. Journal of Clinical Oncology, 2016, 34, 3576-3576.	1.6	1
98	Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic. Oncology & Hematology Review, 2019, 15, 33.	0.2	1
99	Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. Acta Oncologica, 2021, 60, 482-490.	1.8	1
100	Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer. JNCI Cancer Spectrum, 2022, 6, .	2.9	1
101	Radioembolization for hepatocellular carcinoma: current role and future directions — the medical oncologist's perspective. Hepatic Oncology, 2015, 2, 117-132.	4.2	0
102	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1033-1048.	3.1	0
103	How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e167-e174.	1.1	0
104	Circulating tumour DNA in early stage colorectal cancer: can blood tell all?. Annals of Translational Medicine, 2019, 7, S358-S358.	1.7	0
105	FORECAST-1: Feasibility of organoid response assessment to define effective treatments for patients with colorectal cancer after failure of standard therapy.. Journal of Clinical Oncology, 2021, 39, e15571-e15571.	1.6	0
106	Reply to: Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not. Annals of Surgical Oncology, 2021, 28, 795-796.	1.5	0
107	Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. Journal of Clinical Oncology, 2013, 31, 534-534.	1.6	0
108	Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, e14608-e14608.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Resection of colorectal cancer (CRC) metastases in routine practice.. Journal of Clinical Oncology, 2014, 32, 599-599.	1.6	0
110	Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care.. Journal of Clinical Oncology, 2014, 32, e17637-e17637.	1.6	0
111	Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer.. Journal of Clinical Oncology, 2014, 32, e14518-e14518.	1.6	0
112	Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia.. Journal of Clinical Oncology, 2015, 33, e14648-e14648.	1.6	0
113	Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 685-685.	1.6	0
114	Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. Growth Factors, 2020, 38, 127-136.	1.7	0
115	Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 47-47.	1.6	0